Cargando…

Cell Therapy for Heart Failure With Preserved Ejection Fraction

Detalles Bibliográficos
Autores principales:	Borlaug, Barry A., Reddy, Yogesh N.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113353/ https://www.ncbi.nlm.nih.gov/pubmed/30167504 http://dx.doi.org/10.1016/j.jacbts.2016.01.004

Ejemplares similares

Understanding Heart Failure With Preserved Ejection Fraction in a Diabetic Way
por: Li, Haobo, et al.
Publicado: (2021)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Identification of Patients with Preclinical Heart Failure with preserved Ejection Fraction Using the H(2)FPEF Score
por: Koepp, Katlyn E., et al.
Publicado: (2022)

Heart Failure With Preserved Ejection Fraction in Women: New Clues to Causes and Treatment
por: Barton, Matthias, et al.
Publicado: (2020)

Heart rate in heart failure with mid-range ejection fraction
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
por: Oduah, Mary-Tiffany, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction: current status and challenges for the future
por: van der Velden, J., et al.
Publicado: (2016)

Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis
por: Fudim, Marat, et al.
Publicado: (2020)

Nutrient Intake and Exercise Capacity in Heart Failure With Preserved Ejection Fraction: Doughnut Assume it Is Only About Diastolic Function
por: Hummel, Scott L., et al.
Publicado: (2017)

Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: AbouEzzeddine, Omar F., et al.
Publicado: (2017)

High‐Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network
por: Fudim, Marat, et al.
Publicado: (2018)

Modelling the complexity of heart failure with preserved ejection fraction
por: O’Gallagher, Kevin, et al.
Publicado: (2018)

Heart Failure With Preserved Ejection Fraction: An Opportunity for Reflection
por: Gupta, Deepak K.
Publicado: (2017)

Strategies for management of heart failure with preserved ejection fraction
por: Winchester, David E.
Publicado: (2019)

Medical Therapy for Heart Failure with Preserved Ejection Fraction
por: Varnado, Sara, et al.
Publicado: (2022)

Impaired Myocardial Oxygen Availability Contributes to Abnormal Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction
por: van Empel, Vanessa P. M., et al.
Publicado: (2014)

Cell Therapy in Heart Failure with Preserved Ejection Fraction
por: Frljak, Sabina, et al.
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine
por: Miñana, Gema, et al.
Publicado: (2021)

Reviving the origins: acoustic biomarkers of heart failure with preserved ejection fraction
por: Tokodi, Márton, et al.
Publicado: (2022)

Diagnosing heart failure with preserved ejection fraction with pulmonary vascular disease
por: Maeder, Micha T
Publicado: (2023)

High Intensity Exercises in Heart Failure with Preserved Ejection Fraction
por: Herdy, Artur Haddad, et al.
Publicado: (2018)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
por: Lewis, Gregory D., et al.
Publicado: (2023)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2013)

Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction
por: Giamouzis, Gregory, et al.
Publicado: (2016)

Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction
por: Edelmann, Frank
Publicado: (2015)

Simultaneous Measurement of Lung Diffusing Capacity and Pulmonary Hemodynamics Reveals Exertional Alveolar‐Capillary Dysfunction in Heart Failure With Preserved Ejection Fraction
por: Fermoyle, Caitlin C., et al.
Publicado: (2021)

Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction
por: Hohendanner, Felix, et al.
Publicado: (2018)

Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. Where to Draw the Line
por: Simon, Marc A., et al.
Publicado: (2019)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Predicting heart failure with preserved ejection fraction: revisiting an old friend with new knowledge
por: van der Boon, Robert M A
Publicado: (2021)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction Is a Still Big Unmet Need in Cardiology
por: Ohte, Nobuyuki
Publicado: (2021)

Obesity and heart failure with preserved ejection fraction (HFprEF): the whole body question
por: eBioMedicine
Publicado: (2023)

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction
por: Samson, Rohan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_frp1782vu9b1cfubjrj4ijc46m